WO2001032915A2

WO2001032915A2 - Reversed-phase hplc assay for plasminogen activators

Info

Publication number: WO2001032915A2
Application number: PCT/US2000/030252
Authority: WO
Inventors: Yuan Xu
Original assignee: Genentech, Inc.
Priority date: 1999-11-04
Filing date: 2000-11-01
Publication date: 2001-05-10
Also published as: NO329876B1; US6828118B2; HU226202B1; CN1167808C; HUP0202973A2; CA2384756C; PL204011B1; CZ302023B6; NO20022122L; MXPA02004401A; BRPI0015283B1; DE60003449T2; SI1226269T1; JP2003513638A; US6593097B1; KR100649043B1; BRPI0015283B8; CA2384756A1; ZA200202687B; PT1226269E

Abstract

A process is described for monitoring the effectiveness of a purification process in removing plasminogen activator (PA) endogenous to Chinese hamster ovary (CHO) cells from a sample containing human tPA or variants thereof. This process comprises incubating the sample with a protease capable of specifically cleaving the Arg275 - Ile276 bond of human wild-type tPA and then with denaturing/reducing agents in respective amounts effective to reduce the disulfide bonds of human wild-type tPA; subjecting the sample to a reversed-phase high-performance liquid chromatography step, and analyzing the elution profile from the chromatography step for the amount of PA endogenous to the CHO cells present therein.

Description

REVE SED-PHASE HPLC ASSAY FOR PLASMINOGEN ACTIVATORS Background of the Invention Field of the Invention

This invention is directed to an assay for determining the amount of Chinese Hamster Ovary (CHO) -produced tPA is present in samples of recombmant human tPA with native sequence or its variants produced n CHO cells. Description of Related Art

Tissue-type plasmmogen activators (tPA) are endogenous seπne proteases involved n a cascade of events leading to the dissolution of a blood clot (Astrup and Permm, Nature, 159, 681-682 (1947); Camiolo et al . , Proc. Soc. Exp. Biol. Med. , 138, 277-280 (1971) ; Collen, J. Biol . Chem. , 33, 77-86 (1987); Hoylaerts et al . , J. Biol. Chem., 257, 2912-2919 (1982)). ACTIVASE⁰ is the recombmant form of human tPA (r-tPA) , used in the management of acute myocardial infarction and pulmonary embolism (Grossbard, Pharm. Res . , 4., 375-378 (1987)). ACTIVASE⁰ is also now approved for treating lschemic stroke (Smith et al . , Acad. Emergency Medicine, .6(6), 618-25 (1999); Kwiatkowski et al . , New Eng. J. Med., 340(23), 1781-1787 (1999)). It is a glycoprotem produced by expressing the complementary DNA (cDNA) for natural human tPA m Chinese hamster ovary (CHO) cells. TNK-tPA is a genetically engineered variant of human tPA cloned and expressed in CHO cells (Keyt et al . , Proc. Natl. Acad. Sci USA., 91, 3670-3674 (1994)). Site-directed mutations were introduced at three specific sites of human tPA to create the TNK-tPA variant. They are Thrl03 to Asn (T103N), Asn 117 to Gin (N117Q) , and Lys-His-Arg-Arg 296-299 to Ala-Ala-Ala-Ala (KHRR296-299AAAA) . When compared to tPA, TNK-tPA exhibits similar m vi tro biological activity, an increased resistance to plasmmogen activator inhibitor and an enhanced fibrin specificity, and is cleared more slowly from plasma (Keyt et al . , Proc. Natl. Acad. Sci USA., 91, 3670-3674 (1994); Thomas et al . , Stroke, 25:10, 2072-2079 ( 1994); Benedict et al . , Circulation, 92:10, 3032- 3040 (1995); Modi et al . , Thromb Haemost, 79, 134-139 ( 1998)). It is currently awaiting regulatory approval as a single bolus administered form of r-tPA. CHO cells biosynthesize endogenous hamster tPA called CHO-PA. CHO-PA has a similar fibπnolytic activity to human tPA as determined by the clot lysis assay. The ammo acid sequence of CHO-PA is 80% identical to that of human tPA. Many of the substitutions are semi-conservative such as: Arg<-->Lys, Glu<-->Asp, Phe<-->Tyr, Val<-->Ala, Ile<—>Leu or Thr<—> Ser. Using a model of the human tPA protease domain based upon the bovine chymotrypsm structure, it is observed that virtually all of the substitutions in CHO-PA are localized at or near the protein surface. r-tPA, TNK-tPA, and CHO-PA are all single polypeptide chains composed of 527 ammo acids with 17 disulfide bonds (Nguyen and Carole, "Stability Characterization and Formulation Development of Altepase, a Recombmant Tissue Plasmmogen Activator," in Stability and Characterization of Protein and Peptide Drugs: Case Histories, Y. J. Wang, R. Pearlman, eds . , (Plenum Press: New York, 1993), pp. 91-135. For all three proteins, the peptide bond between Arg₂₇₅ and Ile₂₇₆ is particularly susceptible to protease cleavage. The cleavage results two fragments: one consisting of the N-termmal 275 ammo acids and the other consisting of the C-termmal 252 ammo acids. The N-termmal chain contains regions which are homologous to the krmgle regions found in plasmmogen and prothrombm and, therefore, is often referred to as the "krmgle fragment" (Nguyen and Carole, supra ; de Vos et al . , Biochem. , 31, 270-279 (1992) ) .

The C-termmal chain contains the catalytically active site and, therefore, is commonly referred to as the "protease fragment" (Pennica et al . , Nature, 301, 214-221 (1983)). The cleaved two chains are linked by a single disulfide bond formed between Cys₂₆₄ and Cys₃₉₅. The cleaved molecule is commonly referred to as "two-chain tPA" as opposed to " single-chain tPA" or the intact form. r-tPA contains four potential sites for N-lmked glycosylation identified by the sequence Asn-X-Ser/Thr (Nguyen and Carole, supra ) . These are Asn₁₁₇, Asn₁₈₄, Asn_218, and Asn₄₄₈. r-tPA exists as two glycosylation isozymes designated type I and type II. Type I r-tPA is glycosylated at Asn₁₁₇, Asn₁₈₄, and Asn₄₄₈; whereas type II r-tPA is glycosylated only at Asn₁₁₇ and Asn₄₄₈. Asn₂₁₈ is not glycosylated m either isoforms. TNK-tPA has the same glycosylation pattern as r-tPA, except that the Thrl03 to Asn and Asnll7 to Gin mutations effectively moved the glycosylation site from position 117 to 103 (Keyt et al . , supra) . The glycosylation pattern for CHO-PA is not fully characterized (Riηken and Collen, J. Biol. Chem., 256: 7035-7041 (1981)

ACTIVASE^® is a trademark for the recombmant form of human tissue-type plasmmogen activator (r-tPA) , used m the management of acute myocardial infarction and pulmonary embolism. ACTIVASE^& brand tPA is also now approved for treating lschemic stroke. It is produced by expressing the complementary DNA (cDNA) for natural human tPA in Chinese hamster ovary (CHO) cells (U.S. Pat. No. 5,753,486) . TNK-tPA is a genetically engineered variant of r-tPA with enhanced efficacy and lower incidence of bleeding compared with ACTIVASE^® r-tPA. It was created by three site-directed mutations (T103N, N117Q and KHRR296-299AAAA) , and is also cloned and expressed in CHO cells (U.S. Pat. No. 5,612,029). CHO cells biosynthesize endogenous hamster tPA called CHO-PA. The ammo acid sequence of CHO-PA is highly homologous (80% identical) to that of r-tPA. All three thrombolytic proteins exist as heterogeneous isoforms, mainly due to proteolysis/hydrolysis and differential glycosylation.

A method for purifying human tPA from CHO-PA is described in U.S. Pat. No. 5,411,864. This method comprises contacting a fluid containing the human tPA with antibodies specifically binding the corresponding endogenous CHO-PA and recovering the human tPA. Preferably the contacting step involves passing the fluid through a chromatographic bed having the antibodies immobilized thereon. The development of recombmant DNA-deπved protein pharmaceuticals has been facilitated by the introduction of new analytical methods that can be used to characterize protein and/or to demonstrate consistency of manufacture of a protein. Peptide mapping is a key method for monitoring the ammo acid sequence and is able to detect small changes small to moderate size proteins, for example, insulin and human growth hormone. The analysis of a much larger protein, e.g., fibrmogen (molecular mass of 350,000), or the heterogeneous glycoprotems, such as antibodies (molecular massof 150,000), is hindered by the complexity of the range of peptides generated by an enzymatic digestion. Such complexity makes a single reversed-phase high-performance liquid chromatography (RP-HPLC) separation combined with on-line ultraviolet detection of limited utility.

The advent of commercially available combined HPLC and electrospray lonization mass spectromety (LC-ES-MS) systems compatible with convention HPLC has increased the power of peptide mapping considerably (Ling et al . , Anal . Chem. , 63: 2909-2915 (1991) ; Guzetta et al . , Anal. Chem. , 65: 2953-2962 (1993) ) . LC-EM-MS in combination with m-source collisionally-mduced dissociation (CID) has been used effectively to identify sites of N- and O-lmked glycosylation (Carr et al . , Protein Sci. , 2: 183-196 (1993); Huddleston et al . , Anal. Chem., 65: 877-884 (1993); Conboy and Henion, J. Am. Soc. Mass Spectrom. , 3: 804-814 (1992)). However, even this technique is limited by insufficient resolution resulting from the large number of very similar peptides caused by variable protein glycosylation and enzymatic digests of moderately- sized glycoprotems. It is therefore necessary to employ a range of techniques with orthogonal selectivity to characterize such samples.

The use of combinations of high-performance capillary electrophoresis, HPLC, LC-ES-MS, and matrix-assisted laser desorption lonization-time of flight mass spectrometry has been investigated to allow for characterization of enzymatic digests of undeπvatized glycoprotem samples, as exemplified by DSPA l, a single-chain plasmmogen activator derived from vampire bat salivary glands (Apffel et al . , J. Chromatography A, 717: 41-60 (1995)). It was concluded that these four techniques are highly complimentary techniques for examining glycoprotems. Nonetheless, the authors acknowledge that more work needs to be done to improve the power of this approach, and that high-yield concentration steps will be required due to extensive carbohydrate heterogeneity.

There is a need for a technique to monitor the relative and absolute amounts of CHO-PA present after a purification procedure for tPA is carried out, such as the one reported in U.S. Pat. No. 5,411,864, supra . Summary of the Invention

Accordingly, a reversed-phase HPLC method was developed herein for the analysis of the three thrombolytic molecules, CHO-tPA, recombmant human tPA with native sequence, and TNK-tPA. This method not only has the ability to resolve human tPA and/or TNK-tPA from CHO-PA, but also is capable of identifying and quantifying different isoforms of each molecule.

Specifically, the present invention provides a process for monitoring the effectiveness of a purification process in removing plasmmogen activator (PA) endogenous to Chinese hamster ovary (CHO) cells from a sample containing human tPA or variants thereof, which process comprises incubating the sample with a protease capable of specifically cleaving the Arg₂₇₅ - Ile₂₇₆ bond of human wild- type tPA and then with denaturing and reducing agents in amounts effective to reduce the disulfide bonds of human wild-type tPA; subjecting the sample to a reversed-phase high-performance liquid chromatography step, and analyzing the elution profile from the chromatography step for the amount of PA endogenous to the CHO cells present therein.

Brief Description of the Drawings Figure 1 shows a reversed-phase HPLC analysis of native r-tPA, TNK-tPA and CHO-PA.

Figure 2 shows a reversed-phase HPLC analysis of DTT/urea treated r-tPA, TNK-tPA and CHO-PA. Plasmmogen activators were treated with DTT/urea prior to chromatography .

Figure 3 shows a reversed-phase HPLC analysis of plasmm and DTT/urea treated r-tPA, TNK-tPA and CHO-PA. Plasmmogen activators were subjected to plasmm treatment followed by DTT/urea treatment prior to chromatography.

Description of the Preferred Embodiments Definitions

The terms "tissue plasmmogen activator", and "tPA" refer to human extrinsic (tissue-type) plasmmogen activator having fibr olytic activity that typically has a structure with five domains (finger, growth factor, krmgle-1, krmgle-2, and protease domains) , but nonetheless may have fewer domains or may have some of its domains repeated if it still functions as a thrombolytic agent and retains the N-lmked glycosylation sites at positions 117, 184, and 448. At minimum, the tPA consists of a protease domain that is capable of converting plasmmogen to plasmm, and an N-termmal region believed to be at least partially responsible for fibrm binding, and retains the N-lmked glycosylation sites at positions corresponding to ammo acid positions 117, 184, and 448 of wild-type human tPA. The retention of these glycosylation sites is due to the fact that variable site occupancy of recombmant and melanoma-derived wild-type tPA leads to production of two variants, designated as "Type I tPA" and "Type

II tPA" , respectively. Type I tPA contains N-lmked oligosacchaπdes at positions 117, 184, and 448. Type II tPA contained N-lmked oligosaccharides at positions 117 and 448. It will be understood that natural allelic variations exist and can occur among individuals, as demonstrated by one or more ammo acid differences in the ammo acid sequence of tPA of each individual.

The terms "wild-type human tissue plasmmogen activator", "wild-type human tPA" , "native human tissue plasmmogen activator," and "native human tPA", where "human tPA" may be abbreviated as "htPA", refer to native-sequence human tPA, i.e., that encoded by the cDNA sequence reported in U.S. Pat. No. 4,766,075, issued 23 August 1988. Ammo acid site numbers or positions m the tPA molecule are labeled in accordance with U.S. Pat. No. 4,766,075. As used herein, references to various domains of tPA mean the domains of wild-type human tPA as heremabove defined, and functionally equivalent portions of human tPA having ammo acid alterations as compared to the native human tPA sequence, or of (native or variant) tPA from other sources, such as bat tissue plasmmogen activator (bat-PA) . Thus, as used herein, the term "protease domain" refers to the region extending from ammo acid position 264 to ammo acid position 527, inclusive, of the mature form of wild-type human tPA, and to functionally equivalent portions of human tPA having ammo acid alterations as compared to the native human tPA sequence, or of tPA from other sources, such as bat-PA. As used herein, "tPA variants" refers to molecules that differ from native tPA by one or more amino acid changes or modifications to existing ammo acids. TNK-tPA is the preferred variant herein. The modification to change or insert the appropriate ammo acιd(s) n the native molecule to effect the desired sequence variations is accomplished by any means known m the art, such as e.g. site-directed mutagenesis or ligation of the appropriate sequence into the DNA encoding the relevant protein.

As used herein, "TNK-tPA" refers to a tPA molecule wherein Thrl03 of wild- type tPA is changed to Asn (T103N) , Asnll7 of wild-type tPA is changed to Gin (N117Q) , and Lys-His-Arg-Arg 296-299 of wild-type tPA is changed to Ala-Ala-Ala- Ala (KHRR296-299AAAA) . Such TNK is further described n U.S. Pat. No. 5,612,029.

The term "Chinese hamster ovary cell" or "CHO cell" refers to cells or cell lines derived from Chinese hamster ovaries, as described, for example, in EP 117,159, published August 29, 1989; U.S. Pat. Nos. 4,766,075; 4,853,330; 5,185,259; Lubmiecki et al . , in Advances m Animal Cell Biology and Technology for Bioprocesses, Spier et al . , eds . (1989), pp. 442-451), as well as CHO derivatives such as CHO/-DHFR (Urlaub and Chasm, Proc. Natl. Acad. Sci. USA, 77: 4216 (1980)), CHO-Kl DUX Bll (Simonsen and Levmson, Proc. Natl. Acad. Sci. USA, 80: 2495-2499 (1983); Urlaub and Chasm, supra ) , and dpl2.CH0 cells (EP 307,247 published 15 March 1989) Preferred host cells include CHO-Kl DUX Bll and dpl2.CHO cells.

The CHO cells developed for large-scale production of tPA are maintained cryogenically in a MCB/workmg cell bank (WCB) system as described by Wiebe et al . , n Large Scale Mammalian Cell Culture Technology, Lubmiecki, ed., (Marcel Dekker: New York, 1990), pp. 147-160. DHFR+ CHO-Kl cells transfected with DNA encoding human tPA have been deposited at the American Type Culture Collection, Manassas, Virginia (ATCC) , and are available under accession number CCL 61. A sample of another tPA-producmg CHO cell line (CHO cell line 1-15₁₅) has been deposited under ATCC accession number CRL 9606. The latter cell line was reported to result in human tPA levels approaching 50 pg/cell/day.

As used herein "CHO plasmmogen activator" or "CHO-PA" refers to plasmmogen activator that is produced endogenously by CHO cells. This endogenous PA expressed by CHO cells has a sequence slightly different (about

80% identical) from the human wild-type tPA. The CHO-PA is not a tissue-type

PA.

As used herein, "protease" refers to an enzyme that is capable of cleaving the Arg_27S - Ile₂₇₆ bond of human wild-type tPA specifically. Examples include plasmm (or plasmmogen, which converts to plasmm), tissue kallikrem, or Factor Xa, as well as any trypsm-like proteases that can effect this specific, limited proteolysis. Eligible proteases are further described in Ichmosi et al . , FEBS Letters, 175: 412-418 (1984). Preferred herein is plasmm/plasmmogen . As used herein, "denaturing/reducing agents" or "denaturing agent and reducing agent" refers to a combination of denaturant and reductant that reduces the disulfide bonds of human wild-type tPA. Preferably, the denaturing agent is guanidme or urea and the reducing agent is dithiothreitol (DTT) or 2- mercaptoethanol . Modes for Carrying Out the Invention

After recombmant production, the tPA or tPA variant is recovered from the CHO culture medium, either as a secreted protein or from host cell lysates when directly expressed without a secretory signal. It is necessary to purify the tPA or variant thereof from host cell proteins to obtain preparations that are substantially homogeneous as to protein. As a first step, the culture medium or lysate is centrifuged or filtered to remove particulate cell debris.

The human tPA or variant thereof is then purified from corresponding contaminant endogenous proteins such as CHO-PA by such techniques as fractionation on lmmunoaffmity or ion- exchange columns as described, for example, m U.S. Pat. No. 5,411,864; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation exchange resm such as DEAE; chromatofocus g; SDS-PAGE; ammonium sulfate precipitation; or gel electrophoresis using, for example, Sephadex G-75. A protease inhibitor that does not interfere with the tPA activity such as phenylmethylsulfonyl fluoride (PMSF) also may be useful to inhibit proteolytic degradation during purification, and antibiotics may be included to prevent the growth of adventitious contaminants. One skilled m the art will appreciate that purification methods suitable for native tPA may require modification to account for changes m the character of tPA or its variants upon expression in recombmant cell culture.

In a preferred embodiment, if a tPA variant is being produced, it is secreted and the supernatant is passed over a PBS-preconditioned column of glass beads coupled to anti-tPA goat polyclonal A6 antibody, the column is equilibrated with a buffer, and the tPA variant is then eluted.

The invention herein is directed to monitoring (including qualifying and quantifying) levels of native CHO-PA in a sample taken from such purification systems that contains at least one form of human tPA that is produced in CHO cells. The process comprises incubating the sample with a protease that is capable of cleaving Arg₂₇₅ - Ile₂₇₆ bond specifically. This is followed by incubation of the protease-treated sample with a combination of a denaturing and reducing agent in proper relative and absolute amounts to effect reduction of the disulfide bonds m human wild-type tPA. Since the treatment with denaturing and reducing agents causes the loss of enzyme activity, the incubation with protease occurs first.

After incubation, the sample is subjected to a reversed-phase high- performance liquid chromatography step, and the elution profile from the chromatography step analyzed for the amount of PA endogenous to the CHO cells present therein. Preferably, the protease is plasmmogen, which converts to the active form, plasmm, the human tPA is native-sequence tPA, and the tPA variant

The consecutive incubation step with the protease followed by the denaturing/reducing agents typically takes place at a temperature of about 30- 40°C, more preferably about 36-38°C, and most preferably about 37°C, for a minimum of about 15 minutes, more preferably about 20-40 minutes.

Also, preferably before incubation, the sample is diluted with a digestion buffer, which preferably has a pH of about 7 to 8, more preferably phosphate buffer at pH 7.4-7.6, and more preferably also containing argin ne.

Any suitable HPLC column on which the sample is loaded may be utilized for the purposes of this invention, including preparative or analytical scale. The column is typically equilibrated for at least about 15 minutes prior to sample injection. Column size, column material, flow rate, elution buffers, type of gradient, injection volume, and particle size of column αepend on various factors, including the size of the sample being examined, the type of mobile phase composition and gradient, and the forms of tPA being distinguished.

The loading solvent may be any solvent but is preferably an acetonitrile- based solvent such as water, acetonitπle, and tπfluoroacetic acid (TFA) . Preferably, the column is a Zorbax C8, Vydac, or Baker C-18 column packed with a medium having a particle diameter of about 4-40 μm, more preferably about 5-15 μm, and a pore size of about 100-4000 A, more preferably about 150-350 A. Also, the medium preferably has a C4, C8, or C18 alkyl group, ana most preferably is a C8 silica medium. Preferably, the elution is carried out with a solvent comprising acetonitπle, such as water, acetonitπle, and TFA, in a gradient format over 60-100 minutes, preferably a linear gradient, wherein the relative amount of acetonitπle is increased in the solvent. In another preferred embodiment, a shallow gradient ramp at about 0.25% acetonitrile per mmute is employed.

If the analysis for purity herein indicates that the technique employed successfully removes CHO-PA, further purification steps can be carried out as necessary to remove any other contaminants. If the technique did not successfully remove CHO-PA to acceptable levels, a different purification scheme can be utilized and the process herein repeated to determine how effective that scheme is.

After final purification, the tPA or variant thereof can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the tPA product is combined in admixture with a pharmaceutically acceptable carrier. Such formulations are well described in the literature as well as dosages and uses. For example, the tPA or its variant is suitably administered parenterally to subjects suffering from cardiovascular diseases or conditions and strokes.

The following examples are intended to illustrate one embodiment now known for practicing the invention, but the invention is not to be considered limited to these examples. All open and patented literature citations herein are expressly incorporated by reference. EXAMPLE 1

MATERIALS

ACTIVASE^® (r-tPA) and TNK-tPA were obtained from Genentech, Inc. (South San Francisco, CA) m a form purified from CHO cells. See also, for example, U.S. Pat. Nos. 4,766,075 and 5,753,486 for ACTIVASE^® r-tPA and US Pat. No. 5,612,029 for TNK-tPA.

Monoclonal antibody #354 for CHO-PA was produced as described in U.S. Pat. No. 5,411,864. Briefly, a female Balb/c mouse was immunized over a period of 12 weeks with protein solutions substantially enriched in CHO plasmmogen activator purified from host cell lacking the human t-PA. There were five injections each consisting of approximately 30 μg . The initial injection was emulsified with complete Freund's adjuvant and administered in subcutaneous sιte(s). The second injection given 1.5 weeks later was emulsified with incomplete Freund's adjuvant and half was administered subcutaneously and half mtraperitoneally . The remaining three injections were given on weeks 3, 6 and 12 in phosphate buffered saline (PBS) administered in one mtraperitoneal site.

The spleen from the immunized mouse was removed on week 13 and spleen cells were fused with the mouse myeloma cell line NP3X63-Ag8.653 using the general procedures of Fazekas et al . , J . Immunol. Methods, 35 : 1 (1980) and

Lane, J. Immunol. Methods 81 : 223 (1985) . The fused cells were distributed into ten microtiter plates each containing 96 wells. Each well was screened for specific antibody production using differential reactivity m two ELISA's (enzyme linked lmmunoadsorbant assays) . One ELISA specifically detected antibodies against CHO-PA and the second detected antibodies that cross-reacted with recombmant human tPA.

Approximately 5% of the total wells were reactive only with CHO-PA, and 3% reacted with CHO-PA and human t-PA. Hybridoma cells from wells containing CHO-PA-specifIC antibodies were expanded and cloned by limiting dilution (Oi and Herzenberg, "Immunoglobm-Producmg Hybrid Cell Lines", p. 351-372, in Selected Methods m Cellular Immunology, Mishell and Shngi, eds . (W. H. Freeman and Co., 1980)). Large quantities of specific monoclonal antibodies were produced by cell culture of the hybridoma cells or by injection of hybridoma cells in mice thereby producing ascites tumors . MAb 354 was one resulting antibody, which lowered CHO-PA levels greater than about 100 fold m a single column pass when immobilized and is stable to several different immobilization chemistries and harsh washing conditions. MAb 354 was purified using the steps set forth below, where all steps were carried out at room temperature. Concentration was carried out as follows: The MAb hybridoma suspension culture harvest fluid (HF) was filtered through a 0.2 μm filter. The culture fluid was concentrated by ultraflltration or by chromatography on an ion-exchange resin. Affinity purification was carried out as follows: Thimerosal was added to the concentrated MAb HF solution to approximately 0.02%. The solution was adjusted to approximately 1.5 M glycme, 3.0 M NaCl, pH 9.0 by addition of 3.0 M glycme, followed by addition of crystalline NaCl. Protein A has poor Ab binding, so addition of NaCl and glycme increases hydrophobic interaction, so as to facilitate Ab binding. The solution was clarified by filtration. The clarified concentrated MAb HF was applied to a column of protein A immobilized to agarose. The bound MAb was washed with the buffer used to equilibrate the column, having the approximate composition of 1.5 M glycme, 3.0 M NaCl, 0.02 M EDTA, pH 9.0. The MAb was eluted with 0.1 M sodium citrate, 0.15 M NaCl, pH 3.0 buffer. The protein A column was regenerated by washing with 3.0 M NaSCN, 0.03 M TRIS, pH 8.5 and re-equilibrated. The eluted MAb peak was collected based on absorbance profile at 280 nm. The citrate-eluted MAb peak was immediately neutralized by collection into buffer with the approximate composition: 1.5 M TRIS-HC1, pH 9.0. After use, the protein A column was unpacked and stored in sealed containers at 2-8°C in approximately 0.02% thimerosal as storage buffer.

The 354 MAb was then buffer exchanged by diaflltration . Diaflltration proceeded until the conductivity and pH were similar to the values for 0.03 M TRIS, 0.05 M NaCl, pH 8.5 buffer. The MAb was subsequently applied to an amon-exchange chromatograpny column containing DEAE-FAST FLOW™ agarose support and washed with 0.03 M TRIS, 0.05 M NaCl, pH 8.5 buffer. The MAb was step eluted with a buffer having the approximate composition: 0.03 M TRIS, 0.15 M NaCl, pH 8.5. The eluted MAb peak was collected based on absorbance profile at 280 nm.

The MAb was filtered (0.2 μm) into sanitized sealable containers and stored below -40°C. Plasmmogen was obtained from Fluka (Switzerland) . HPLC-grade acetonitrile was obtained from Burdick & Jackson (Muskgon, MI) and tπfluoroacetic acid (TFA) was from Pierce (Rockford, IL) . Water for the HPLC mobile phase and sample solutions was purified with a MILLI-Q™ system from Millipore (Milford, MA) . All other chemicals were of reagent grade from Sigma (St. Louis, MO). METHODS

Purification of CHO-PA

CHO-PA was isolated from CHO cell culture fluid by affinity chromatography followed by lmmunoabsorption. Lysme hyper D resm from BioSepra (Paris, France) was used for the affinity chromatography, as lysme binds to the krmgle 2 region of plasmmogen activators (Cleary et al . , Biochem. 28, 1884-1890 (1989) ) . The lmmunoabsorption was conducted by using CHO-PA specific monoclonal antibody #354 (MAb#354) . MAb#354 was coupled to CNBr-activated SEPHAROSE 4B™ gel according to the vendor's protocol (Pharmacia Biotech, Piscataway, NJ) . About 10 mg of MAb #354 was coupled to per ml of the CNBr-activated Sepharose 4B gel. After coupling, a MAb#354-SEPHAROSE 4B™ column was packed.

CHO cell culture fluid containing secreted CHO-PA was loaded onto a lysme-affinity column pre-equilibrated with an equilibration buffer containing 50 mM sodium phosphate and 0.01% POLYSORBATE 80™ detergent at pH 7.5. After loading, the lysme-affmity column was washed three times: first with the equilibration buffer, followed by a buffer containing 40 mM TRIS, 800 mM NaCl, and 0.008% POLYSORBATE 80™ at pH 8.0, and finally with the equilibration buffer. CHO-PA was then eluted from the lysme affinity column with a buffer containing 50 mM sodium phosphate, 200 mM L-argmme, and 0.01% POLYSORBATE 80™ at pH 7.5. After equilibrating with phosphate-buffered saline (PBS, 8 g/L NaCl, 0.2 g/L KC1, 1.44 g/L Na₂HP0₄ and 0.24 g/L KH₂P0₄ at pH 7.4), the MAb#354-SEPHAROSE™ 4B column was loaded with the lysme-affinity column elution pool. After loading, the column was washed with a buffer containing 9.5 mM Na₂HP0₄, 1 M NaCl, and 5% propylene glycol (v/v) at pH 7.4. The bound CHO-PA was eluted from the column with 0.2 M glycme-HCl at pH 2.5. The elution was monitored spectrophotometπcally at 280 nm and the CHO-PA- containing fractions were neutralized with 0.14 volumes of 1.5 M argmme-phosphate (pH 8.0) immediately upon collection. The identity and purity of the eluted CHO-PA was confirmed by SDS-PAGE and ammo ac d sequence analysis. DTT/urea treatment The solution containing plasmmogen activator (s) was diluted 1:1 (v/v) with a denaturation buffer (8 M urea, 0.5 M TRIS, and 3.2 mM EDTA at pH 8.4). Dithiothreitol (DTT) was added from a 1 M stock solution to a final concentration of 20 mM, and the mixture was incubated at 37°C for 30 mm. Plasmm treatment

The solution containing plasmmogen activator (s) was diluted 1:3 (v/v) with the digestion buffer (125 mM Na₂HP0₄, 200 mM argmme, and 0.01% NaN₃ at pH 7.5). One hundredth (w/w) of plasmmogen was added, and the mixture was incubated at 37°C for 30 mm.

Reversed-phase HPLC assay for plasmmogen activators

The assay was performed on a Hewlett-Packard 1090M™ HPLC system (Hewlett Packard, Avondale, PA) with a 4.6 mm x 250 mm, 5-μm particle size, 300 A pore resm, Zorbax SB-C8 column (Mac-Mod, Chadds Ford, PA) . The column was equilibrated for at least 15 minutes prior to sample injection. The initial mobile phase composition was 70/30/0.1 (v/v/v) of water/acetonitrile/TFA. After a five-mmute initial hold, a linear gradient was performed in 80 minutes (for Figs. 1 and 2) and in 60 minutes (for Fig. 3) to 50/50/0.1 (v/v/v) of water/acetonitrile/TFA. Immediately following the gradient, the column was regenerated for 10 minutes with 100/0.1 (v/v) of acetonitπle/TFA. The composition was then brought back to the initial conditions m 5 minutes, and the system was re-equilibrated for the next injection. The injection volume was 250 rtiL, and the flow rate was 1 mL/min. The chromatography was conducted at 40°C. Fluorescence was measured with a Hewlett-Packard 1046A™ programmable fluorescence detector (Ex = 275 nm and Em = 340 nm) . The chromatograms were recorded and analyzed with Hewlett-Packard CHEMSTATION™ software. RESULTS AND DISCUSSION

Due to high sequence homology, ACTIVASE^® (r-tPA) , TNK-tPA, and CHO-PA have very similar biochemical/biophysical properties. Analytical and preparative methods capable of resolving these three plasmmogen activators from each other or capable of resolving tPA from CHO-PA or TNK-tPA from CHO-PA are needed for recovery process development and to estimate the purity of each molecule for clinical studies and commercial production. Described herein is a simple reverse-phase HPLC method that accomplishes these goals. With a shallow gradient ramp at 0.25% acetonitrile per mmute and no protease or denaturing/reducing agents, reversed-phase HPLC was not able to separate the native form of r-tPA from native CHO-PA (Figure 1). However, the native form of TNK-tPA was resolved very well from both native r-tPA and CHO-PA under these conditions. Next, DTT/urea treatment was performed to reduce the disulfide bonds and denature the proteins. For all three proteins, the peptide bond between Arg₂₇₅ and Ile₂₇₆ is very susceptible to protease cleavage. Over time, this susceptibility leads to heterogeneity for r-tPA, TNK-tPA, and CHO-PA m solution. A small amount of the single-chain form is converted to the two- chain form due to the protease cleavage. DTT/urea treatment reduces the disulfide bond between Cys₂₆₄ and Cys₃₉₅ that holds the two-chain form of the molecule together, resulting m the dissociation of the molecule into two fragments (the krmgle fragment and the protease fragment) . Figure 2 shows that, under the same gradient ramp, reversed-phase HPLC was able to resolve the single-chain form of the three thrombolytic molecules from each other after DTT/urea treatment. All three proteins exhibited similar elution profiles with the krmgle fragment of the two-chain form eluting first, the single-chain form eluting second, and the protease fragment of the two-chain form eluting last. The respective protease fragments of the three plasmmogen activators were also well resolved from each other, while the krmgle fragments for the three molecules were not well separated. Consequently, this method can be used to detect and quantify the fragmentation of the single-chain form into the two-chain form of the plasmmogen activators.

The heterogeneity observed in the r-tPA, TNK-tPA, and CHO-PA profiles (Figure 2) makes the quantification of these molecules very difficult, especially when trying to quantify each individual molecule in a mixture of rtPA, TNK-tPA, and CHO-PA. To eliminate the heterogeneity associated with proteolysis, all of the single-chain form was converted to two-chain form by incubating with plasmmogen. Plasmmogen is the substrate of plasmmogen activator m the natural fibrmolytic system. r-tPA, TNK-tPA, and CHO-PA all have the enzymatic activity of cleaving the Arg₅₆₀-Val₅₆₁ peptide bond of plasmmogen. Such cleavage converts plasmmogen into its active form, plasmm. Plasmm is a ser ne protease with low specificity and is capable of cleaving the Arg₂₇₅-Ile₂₇₆ peptide bond m r-tPA, TNK-tPA, and CHO-PA. As a result, incubation with plasmmogen converts the single-chain form of the three plasmmogen activators to the two-chain form.

Following the plasmm treatment, the samples were treated with DTT/urea to reduce disulfide bonds and thus dissociate the two-chain form of the molecule into two discrete fragments. Figure 3 shows the reversed-phase HPLC profiles for the plasmm- and DTT/urea-treated plasmmogen activators. The respective protease fragments of the three proteins were well separated from each other, while the krmgle fragments of the three molecules were not resolved. Therefore, the protease fragment was used for the integration and quantification of each plasmmogen activator. For both r-tPA and TNK-tPA, the krmgle fragments from the type I and type II isozymes were well separated. As a result, this method is also useful for the quantification of the type I to type II ratio for both r-tPA and TNK-tPA. The availability of this reversed-phase HPLC method greatly facilitates the manufacturing process development. It has been used to evaluate the effect of different fermentation conditions on product quality regarding the integrity of the product (i.e. single chain percent) and the ratio of type I and type II isozymes. It has also been used to aid the purification process development and to ensure consistency between production batches. All those applications exemplify the crucial role of analytical and commercial methods in the development of new pharmaceutics.

Claims

WHAT IS CLAIMED IS:

1. A process for monitoring the effectiveness of a purification process m removing plasmmogen activator (PA) endogenous to Chinese hamster ovary (CHO) cells from a sample containing human tPA or variants thereof, which process comprises mcubatmg the sample with a protease capable of specifically cleaving the Arg₂₇₅ - Ile₂₇₆ bond of human wild-type tPA and then with a denaturing agent and a reducing agent in amounts effective to reduce the disulfide bonds of human wild-type tPA; subjecting the sample to a reversed-phase high-performance liquid chromatography step, and analyzing the elution profile from the chromatography step for the amount of PA endogenous to the CHO cells present therein.

2. The process of claim 1 wherein the protease is plasmmogen.

3. The process of claim 1 wherein the human tPA is native-sequence tPA.

4. The process of claim 1 wherein the tPA variant is TNK-tPA.

5. The process of claim 1 wherein before incubation, the sample is diluted with a digestion buffer.

6. The process of claim 5 wherein the buffer has a pH of about 7 to 8.

7. The process of claim 6 wherein the buffer is a phosphate buffer.

8. The process of claim 7 wherein the buffer further comprises argmme.

9. The process of claim 1 wherein the denaturing agent comprises urea or guanidme.

10. The process of claim 1 wherein the reducing agent comprises dithiothreitol or 2-mercaptoethanol.

11. The process of claim 1 wherein the chromatography step is carried out by eluting with a solvent comprising acetonitrile m a gradient format.